We’ve put some small files called cookies on your device to make our site work.
We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.
Change my preferences
I'm OK with analytics cookies
Rituximab is recommended to be available as a routine commissioning treatment option for IgM paraproteinaemic demyelinating peripheral neuropathy in adults within the criteria set out in these documents.